We report a case of a 59-year-old woman with metastatic carcinoma of the ileocecal region who received FOLFOX(oxaliplatin/leucovorin/5-fluorouracil) and bevacizumab therapy and exhibited a partial remission with minimal side effects. She developed a mild self-limited episode of immune-mediated hemolytic anemia during her 16th cycle of chemotherapy, which precluded her from receiving further oxaliplatin. We review the literature on oxaliplatin-induced immune-mediated hemolysis, including its mechanism, presenting symptoms, laboratory features, management, and implications for future therapy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3816/ccc.2005.n.041 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Oxidative stress induces plasma membrane phosphatidylserine externalization in canine erythrocytes in vitro, mitigated by thiol antioxidants.
Am J Vet Res
January 2025
Department of Veterinary Clinical Sciences, College of Veterinary Medicine, Purdue University, West Lafayette, IN.
Objective: To determine if oxidative stress induces phosphatidylserine (PS) externalization in canine erythrocytes and if exposure to antioxidants prevents such changes.
Methods: This was an in vitro, experimental study using 5 healthy, adult, purpose-bred research Beagles. Fresh EDTA-anticoagulated blood samples were collected from each dog, and erythrocytes were harvested.
Successful Management of Severe and Refractory Autoimmune Hemolytic Anemia (AIHA) in a Sickle Cell Disease Patient With Bortezomib.
Cureus
November 2024
Hematology and Medical Oncology, Al-Zahraa Medical College, Basrah, IRQ.
Autoimmune hemolytic anemia (AIHA) is a multifactorial disease that causes immune-mediated red blood cell destruction, resulting in anemia and hemolysis symptoms. Despite a significant understanding of its pathogenesis, the precise causes of AIHA remain largely unclear and are thought to be multifactorial. In this paper, we presented a case of sickle cell anemia who developed severe AIHA that failed to maintain response to multiple treatment lines, including steroids, intravenous immunoglobulin, rituximab, and immune suppressive medications.
View Article and Find Full Text PDFA Case of Thrombotic Microangiopathy Secondary to Hypertensive Emergency: Presentation, Management, and Distinguishing Features.
Cureus
November 2024
Department of Medicine, Mercyhealth Graduate Medical Education (GME) Consortium, Rockford, USA.
Thrombotic microangiopathies (TMA) are a group of conditions that present with varying degrees of microthrombi, thrombocytopenia, microangiopathic hemolytic anemia, renal dysfunction, and neurological impairment. Etiologies can be primary, such as thrombotic thrombocytopenic purpura (TTP), hemolytic uremic syndrome (HUS), and atypical hemolytic uremic syndrome (aHUS), or secondary, such as due to systemic infections, malignancies, immune-mediated conditions, and hypertensive emergencies. In hypertensive emergencies, this presentation can occur from mechanical stress placed on red blood cells as they pass through narrowed arteries due to edema and microangiopathic changes within the vessels themselves.
View Article and Find Full Text PDFObserver reliability in counting erythrocyte ghost cells and impact of short-term storage of canine and feline blood samples.
Vet J
December 2024
Department of Veterinary Clinical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Dyrlaegevej 16, Frederiksberg C DK-1870, Denmark.
The presence of erythrocyte ghost cells (EG) in blood smears indicates intravascular haemolysis or in-vitro haemolysis. However, observer reliability in detection of EG has not been documented. Immediate blood smear preparation is advised but may not always be practical.
View Article and Find Full Text PDFEtiology and Outcomes of Kidney-Limited and Systemic Thrombotic Microangiopathy.
Mod Pathol
December 2024
Expert Center for Immune-mediated Kidney Diseases and Vasculitis, Maastricht University Medical Center, Maastricht, The Netherlands; Department of Biochemistry, Cardiovascular Research Institute Maastricht, Maastricht, The Netherlands. Electronic address:
Article Synopsis
- Thrombotic microangiopathy (TMA) syndromes can lead to serious kidney issues like acute kidney injury and end-stage disease, often marked by low platelet counts and hemolytic anemia.
- A study examined different types of kidney-limited TMA and their outcomes, finding that a significant portion (66%) of patients had this particular form, with distinct characteristics in those with complement-related TMA compared to other types.
- Results showed that treatments like eculizumab were beneficial for kidney-limited complement-mediated TMA, emphasizing the importance of kidney biopsies for early detection and the need to assess for complement issues to guide treatment options.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!